Ticlopidine induced prolonged leucopenia in a patient with immunocytoma and chronic hepatitis C

Vasa - Journal of Vascular Diseases

Volumn 28, Issue 4, 1999, Pages 301-303

  Redlich, K ^b   Parschalk, B ^b   Ehringer, H ^b   Minar, Erich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Hepatitis C; Immunocytoma; Neutropenia; Ticlopidine

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TICLOPIDINE;

AGED; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOCYTOMA; LEUKOCYTE COUNT; LEUKOPENIA; NEUTROPENIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROPHYLAXIS;

EID: 0032716441     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.28.4.301     Document Type: Article

References (8)

1. Camitta BM, Storb R, Thomas ED. Aplastic anemia (1st of two parts): Pathogenesis, diagnosis, treatment and prognosis. N Engl J Med 1982; 306: 645-52.
2. DiMinno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75: 328-38.
3. Goyan JE. Ticlopidine: quo vadis? Adverse reactions in man. Agents Actions 1984; 15 (Suppl): 116-25.
4. Lieschke GJ, Burgess AW. Granulocyte-colony stimulating factor and granulocyte-macrophage-colony stimulating factor (2nd of two parts). N Engl J Med 1992; 327: 99-106.
5. Nand S, Bayer R, Prinz RA, Felten W, Godwin J. Granulocyte-macrophage colony stimulating factor for the treatment of drug induced agranulocytosis. Am J Hematol 1991; 37: 267-69.
6. Pol S, Driss F, Devergie A, Brechot C, Gluckman E. Is hepatitis C virus involved in hepatitis associated aplastic anemia? Ann Intern Med 1990; 113: 435-37.
7. Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in plateled dependent diseases stages. Drugs 1987; 34: 222-62.
8. Schrör K. Antiplatelet drugs. A comparative review. Drugs 1995; 50: 7-28.